BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, Garrido C, Aubin F, Gobbo J. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles 2020;9:1710899. [PMID: 32002173 DOI: 10.1080/20013078.2019.1710899] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 21.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang P, Hu W, Zhu Y, Wu Y, Lin H. The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis. Front Oncol 2020;10:626932. [PMID: 33718120 DOI: 10.3389/fonc.2020.626932] [Reference Citation Analysis]
2 Leetanaporn K, Hanprasertpong J, Navakanitworakul R. Molecular insights and clinical impacts of extracellular vesicles in cancer. Oncol Rev 2021;15:542. [PMID: 34667488 DOI: 10.4081/oncol.2021.542] [Reference Citation Analysis]
3 Morrissey SM, Yan J. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. Trends Cancer 2020;6:550-8. [PMID: 32610067 DOI: 10.1016/j.trecan.2020.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
4 Lucibello G, Mograbi B, Milano G, Hofman P, Brest P. PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends Mol Med 2021:S1471-4914(21)00152-0. [PMID: 34187739 DOI: 10.1016/j.molmed.2021.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Schubert A, Boutros M. Extracellular vesicles and oncogenic signaling. Mol Oncol 2021;15:3-26. [PMID: 33207034 DOI: 10.1002/1878-0261.12855] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Del Re M, van Schaik RHN, Fogli S, Mathijssen RHJ, Cucchiara F, Capuano A, Scavone C, Jenster GW, Danesi R. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochim Biophys Acta Rev Cancer 2021;1875:188463. [PMID: 33137405 DOI: 10.1016/j.bbcan.2020.188463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rasihashemi SZ, Rezazadeh Gavgani E, Majidazar R, Seraji P, Oladghaffari M, Kazemi T, Lotfinejad P. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. J Cell Physiol 2021. [PMID: 34825383 DOI: 10.1002/jcp.30645] [Reference Citation Analysis]
8 Chen X, Du Z, Huang M, Wang D, Fong WP, Liang J, Fan L, Wang Y, Yang H, Chen Z, Hu M, Xu R, Li Y. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. Cancer Immunol Immunother 2021. [PMID: 34322779 DOI: 10.1007/s00262-021-03021-3] [Reference Citation Analysis]
9 He Y, Wu Y, Wang Y, Wang X, Xing S, Li H, Guo S, Yu X, Dai S, Zhang G, Zeng M, Liu W. Applying CRISPR/Cas13 to Construct Exosomal PD‐L1 Ultrasensitive Biosensors for Dynamic Monitoring of Tumor Progression in Immunotherapy. Adv Therap 2020;3:2000093. [DOI: 10.1002/adtp.202000093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol 2021;22:560-70. [PMID: 33753940 DOI: 10.1038/s41590-021-00899-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Valencia K, Montuenga LM. Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology. Cancers (Basel) 2021;13:2147. [PMID: 33946893 DOI: 10.3390/cancers13092147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang L, Sun J. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. Front Immunol 2021;12:665133. [PMID: 33936103 DOI: 10.3389/fimmu.2021.665133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Garutti M, Bonin S, Buriolla S, Bertoli E, Pizzichetta MA, Zalaudek I, Puglisi F. Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. Cancers (Basel) 2021;13:1819. [PMID: 33920288 DOI: 10.3390/cancers13081819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tomela K, Pietrzak B, Schmidt M, Mackiewicz A. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life (Basel) 2020;10:E219. [PMID: 32992737 DOI: 10.3390/life10100219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zebrowska A, Widlak P, Whiteside T, Pietrowska M. Signaling of Tumor-Derived sEV Impacts Melanoma Progression. Int J Mol Sci 2020;21:E5066. [PMID: 32709086 DOI: 10.3390/ijms21145066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
16 Vautrot V, Bentayeb H, Causse S, Garrido C, Gobbo J. Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. Cancers (Basel) 2021;13:4537. [PMID: 34572764 DOI: 10.3390/cancers13184537] [Reference Citation Analysis]
17 Wang J, Zhang H, Sun X, Wang X, Ren T, Huang Y, Zhang R, Zheng B, Guo W. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. J Nanobiotechnology 2020;18:151. [PMID: 33092576 DOI: 10.1186/s12951-020-00710-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Liu J, Ren L, Li S, Li W, Zheng X, Yang Y, Fu W, Yi J, Wang J, Du G. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B 2021;11:2783-97. [PMID: 34589397 DOI: 10.1016/j.apsb.2021.01.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Pucci M, Raimondo S, Urzì O, Moschetti M, Di Bella MA, Conigliaro A, Caccamo N, La Manna MP, Fontana S, Alessandro R. Tumor-Derived Small Extracellular Vesicles Induce Pro-Inflammatory Cytokine Expression and PD-L1 Regulation in M0 Macrophages via IL-6/STAT3 and TLR4 Signaling Pathways. Int J Mol Sci 2021;22:12118. [PMID: 34829995 DOI: 10.3390/ijms222212118] [Reference Citation Analysis]
20 Whiteside TL, Diergaarde B, Hong CS. Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology. Int J Mol Sci 2021;22:6234. [PMID: 34207762 DOI: 10.3390/ijms22126234] [Reference Citation Analysis]
21 Liang B, Hu X, Ding Y, Liu M. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets. J Cell Physiol 2021;236:4138-51. [PMID: 33275291 DOI: 10.1002/jcp.30197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
22 Arasi MB, Pedini F, Valentini S, Felli N, Felicetti F. Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis. Cancers (Basel) 2020;12:E2893. [PMID: 33050185 DOI: 10.3390/cancers12102893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Zhou E, Li Y, Wu F, Guo M, Xu J, Wang S, Tan Q, Ma P, Song S, Jin Y. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine 2021;67:103365. [PMID: 33971402 DOI: 10.1016/j.ebiom.2021.103365] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Maisano D, Mimmi S, Russo R, Fioravanti A, Fiume G, Vecchio E, Nisticò N, Quinto I, Iaccino E. Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. Pharmaceuticals (Basel) 2020;13:E180. [PMID: 32759810 DOI: 10.3390/ph13080180] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
25 Pietrowska M, Zebrowska A, Gawin M, Marczak L, Sharma P, Mondal S, Mika J, Polańska J, Ferrone S, Kirkwood JM, Widlak P, Whiteside TL. Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. J Extracell Vesicles 2021;10:e12063. [PMID: 33613873 DOI: 10.1002/jev2.12063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Ying H, Zhang X, Duan Y, Lao M, Xu J, Yang H, Liang T, Bai X. Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacol Res 2021;170:105741. [PMID: 34174446 DOI: 10.1016/j.phrs.2021.105741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhan R, Wang S, Guo W, Gao X, Liu X, Xu K, Tang B. A simple, rapid and low-cost qPCR assay for evaluating the severity of exosomal PD-L1-mediated T cell exhaustion in blood samples. Chem Commun (Camb) 2021. [PMID: 34931643 DOI: 10.1039/d1cc06496g] [Reference Citation Analysis]
28 Ma F, Vayalil J, Lee G, Wang Y, Peng G. Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. J Immunother Cancer 2021;9:e003217. [PMID: 34642246 DOI: 10.1136/jitc-2021-003217] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Awadasseid A, Wu Y, Zhang W. Extracellular Vesicles (Exosomes) as Immunosuppressive Mediating Variables in Tumor and Chronic Inflammatory Microenvironments. Cells 2021;10:2533. [PMID: 34685513 DOI: 10.3390/cells10102533] [Reference Citation Analysis]
30 Shao B, Dang Q, Chen Z, Chen C, Zhou Q, Qiao B, Liu J, Hu S, Wang G, Yuan W, Sun Z. Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. Front Cell Dev Biol 2021;9:760211. [PMID: 34722545 DOI: 10.3389/fcell.2021.760211] [Reference Citation Analysis]
31 Li JW, Shi D, Wan XC, Hu J, Su YF, Zeng YP, Hu ZJ, Yu BH, Zhang QL, Wei P, Zhou XY. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. Oncoimmunology 2021;10:1995166. [PMID: 34745768 DOI: 10.1080/2162402X.2021.1995166] [Reference Citation Analysis]
32 Ayala-Mar S, Donoso-Quezada J, González-Valdez J. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. J Immunol Res 2021;2021:8839978. [PMID: 33628854 DOI: 10.1155/2021/8839978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zhou B, Gao S. Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker. Front Mol Biosci 2021;8:648402. [PMID: 33968987 DOI: 10.3389/fmolb.2021.648402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Czystowska-Kuzmicz M, Whiteside TL. The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. Expert Opin Biol Ther 2021;21:241-58. [PMID: 32813990 DOI: 10.1080/14712598.2020.1813276] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
35 Battaglia L, Scomparin A, Dianzani C, Milla P, Muntoni E, Arpicco S, Cavalli R. Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape. Pharmaceutics 2021;13:1617. [PMID: 34683910 DOI: 10.3390/pharmaceutics13101617] [Reference Citation Analysis]
36 Srivastava A, Rathore S, Munshi A, Ramesh R. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy. AAPS J 2021;23:30. [PMID: 33586060 DOI: 10.1208/s12248-021-00554-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Abu N, Rus Bakarurraini NAA. The interweaving relationship between extracellular vesicles and T cells in cancer. Cancer Lett 2021:S0304-3835(21)00614-5. [PMID: 34906625 DOI: 10.1016/j.canlet.2021.12.007] [Reference Citation Analysis]
38 Han J, Xu X, Liu Z, Li Z, Wu Y, Zuo D. Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. International Immunopharmacology 2020;88:106971. [DOI: 10.1016/j.intimp.2020.106971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Olejarz W, Dominiak A, Żołnierzak A, Kubiak-Tomaszewska G, Lorenc T. Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. J Immunol Res 2020;2020:6272498. [PMID: 32537468 DOI: 10.1155/2020/6272498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
40 Zhang S, Wang J, Qu MJ, Wang K, Ma AJ, Pan XD, Zhu XY. Novel Insights into the Potential Diagnostic Value of Circulating Exosomal IncRNA-Related Networks in Large Artery Atherosclerotic Stroke. Front Mol Biosci 2021;8:682769. [PMID: 34095232 DOI: 10.3389/fmolb.2021.682769] [Reference Citation Analysis]
41 Kamińska P, Buszka K, Zabel M, Nowicki M, Alix-Panabières C, Budna-Tukan J. Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. Int J Mol Sci 2021;22:9714. [PMID: 34575876 DOI: 10.3390/ijms22189714] [Reference Citation Analysis]
42 Wan Z, Dong Y, Wei M, Gao X, Yang G, Zhang J, Liu L. Exosomes in Tumor Immunotherapy: Mediator, Drug Carrier, and Prognostic Biomarker. Adv Biosys 2020;4:2000061. [DOI: 10.1002/adbi.202000061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Melnik BC, John SM, Carrera-Bastos P, Schmitz G. MicroRNA-21-Enriched Exosomes as Epigenetic Regulators in Melanomagenesis and Melanoma Progression: The Impact of Western Lifestyle Factors. Cancers (Basel) 2020;12:E2111. [PMID: 32751207 DOI: 10.3390/cancers12082111] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
44 Pretti MAM, Bernardes SS, da Cruz JGV, Boroni M, Possik PA. Extracellular vesicle-mediated crosstalk between melanoma and the immune system: Impact on tumor progression and therapy response. J Leukoc Biol 2020;108:1101-15. [PMID: 32450618 DOI: 10.1002/JLB.3MR0320-644R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Zhou K, Guo S, Li F, Sun Q, Liang G. Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. Front Cell Dev Biol 2020;8:569219. [PMID: 33178688 DOI: 10.3389/fcell.2020.569219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
46 Holcar M, Kandušer M, Lenassi M. Blood Nanoparticles - Influence on Extracellular Vesicle Isolation and Characterization. Front Pharmacol 2021;12:773844. [PMID: 34867406 DOI: 10.3389/fphar.2021.773844] [Reference Citation Analysis]
47 Shklovskaya E, Rizos H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. Int J Mol Sci 2020;21:E7139. [PMID: 32992658 DOI: 10.3390/ijms21197139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 Bollard SM, Casalou C, Goh CY, Tobin DJ, Kelly P, McCann A, Potter SM. Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response. Pharmaceuticals (Basel) 2020;13:E475. [PMID: 33353043 DOI: 10.3390/ph13120475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Urabe F, Kimura T, Ito K, Yamamoto Y, Tsuzuki S, Miki J, Ochiya T, Egawa S. Urinary extracellular vesicles: a rising star in bladder cancer management. Transl Androl Urol 2021;10:1878-89. [PMID: 33968676 DOI: 10.21037/tau-20-1039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Parada N, Romero-Trujillo A, Georges N, Alcayaga-Miranda F. Camouflage strategies for therapeutic exosomes evasion from phagocytosis. J Adv Res 2021;31:61-74. [PMID: 34194832 DOI: 10.1016/j.jare.2021.01.001] [Reference Citation Analysis]
51 De Almeida S, Regimbeau M, Jego G, Garrido C, Girodon F, Hermetet F. Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers (Basel) 2020;12:E2592. [PMID: 32932806 DOI: 10.3390/cancers12092592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Claridge B, Lozano J, Poh QH, Greening DW. Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities. Front Cell Dev Biol 2021;9:734720. [PMID: 34616741 DOI: 10.3389/fcell.2021.734720] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Petrova V, Arkhypov I, Weber R, Groth C, Altevogt P, Utikal J, Umansky V. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. Int J Mol Sci 2020;21:E2367. [PMID: 32235439 DOI: 10.3390/ijms21072367] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
54 Ye L, Zhu Z, Chen X, Zhang H, Huang J, Gu S, Zhao X. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target. Cells 2021;10:3247. [PMID: 34831468 DOI: 10.3390/cells10113247] [Reference Citation Analysis]
55 Theodoraki MN, Laban S, Jackson EK, Lotfi R, Schuler PJ, Brunner C, Hoffmann TK, Whiteside TL, Hofmann L. Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients. Br J Cancer 2021. [PMID: 34642463 DOI: 10.1038/s41416-021-01567-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Russo A, Incorvaia L, Del Re M, Malapelle U, Capoluongo E, Gristina V, Castiglia M, Danesi R, Fassan M, Giuffrè G, Gori S, Marchetti A, Normanno N, Pinto C, Rossi G, Santini D, Sartore-Bianchi A, Silvestris N, Tagliaferri P, Troncone G, Cinieri S, Beretta GD. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. ESMO Open 2021;6:100164. [PMID: 34091263 DOI: 10.1016/j.esmoop.2021.100164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Kugeratski FG, Kalluri R. Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS J 2021;288:10-35. [PMID: 32910536 DOI: 10.1111/febs.15558] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
58 Zhang C, Fan Y, Che X, Zhang M, Li Z, Li C, Wang S, Wen T, Hou K, Shao X, Liu Y, Qu X. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. Front Oncol 2020;10:760. [PMID: 32528882 DOI: 10.3389/fonc.2020.00760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
59 Boyer M, Cayrefourcq L, Dereure O, Meunier L, Becquart O, Alix-Panabières C. Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. Cancers (Basel) 2020;12:E960. [PMID: 32295074 DOI: 10.3390/cancers12040960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
60 Hofmann L, Ludwig S, Vahl JM, Brunner C, Hoffmann TK, Theodoraki MN. The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. Int J Mol Sci 2020;21:E4072. [PMID: 32517240 DOI: 10.3390/ijms21114072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]